What is Telotristat Ethyl?
Telotristat Ethyl is a significant introduction to the treatment of Carcinoid Syndrome diarrhea. It’s the first addition to the standard of care in more than 16 years and the first time an oral syndrome treatment has been developed. The drug was previously known as Telotristat Etiprate but was changed to Ethyl in Oct 2016. ‘Etiprate’ was previously a truncation of ‘ethyl hippurate’. The brand name is XERMELO®
1st Aug 2020 Transfer of Ownership
In a move that Lexicon Pharmaceuticals Inc. chief Lonnel Coats said will focus the company on its phase II neuropathic pain program, The Woodlands, Texas-based venture has agreed to sell one of its two approved products, the carcinoid syndrome diarrhea therapy Xermelo (telotristat ethyl), to TerSera Therapeutics LLC. I don’t expect this to make any difference to the drug or its supply. Business as usual. The outer package may change to reflect new owners but the brand name XERMELO will most likely be part of the sale.
Read the news from Lex Pharma – click here.
Who is the drug for?
The drug may be of benefit to those whose carcinoid syndrome diarrhea is not adequately controlled by somatostatin analogues (Octreotide/Lanreotide). It doesn’t replace somatostatin analogues – it is an additional treatment alongside.
Where is it currently approved?
The US FDA approved the drug 28 February 2017.
On 19 September 2017,the European Commission approved Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy after the scientific committee of the EMA (known as Committee for Medicinal Products for Human Use (CHMP)) adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The Ipsen press release is here.
This does not mean all EU countries will use it. Clearly some action will be required in EU national countries before the drug becomes available through appropriate healthcare systems.
On 17 Oct 2018, Health Canada announced approval for NET patients – click here.
UK. 8th January 2020. NHS England did not approve Xermelo with the following statement:
“NHS England has carefully reviewed the evidence to treat CS diarrhoea with telotristat. We have concluded that there is not enough evidence to make the treatment available at this time”. NHS Scotland and Wales have authorised it for “Restricted use”. Restricted use means a narrow meaning to approval, perhaps a particular subset of patients who would benefit most. There is no data about Northern Ireland.
For all other countries please note that Ipsen will pursue a worldwide regulatory plan for marketing authorisation submissions in the territories in which it operates. Once approved, Ipsen will be distributing the drug in all countries, less USA and Japan where Lexicon retains the rights. Outside the USA and Europe will be constrained by national approval timelines.
How does it work?
In the simplest of terms, the drug is an inhibitor of the enzyme tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in serotonin synthesis which converts tryptophan (an essential amino acid which comes from diet) to 5-hydroxytryptophan, which is subsequently converted to serotonin, one of the main causes of carcinoid syndrome effects including carcinoid heart disease. The trial data indicates that Telotristat ethyl significantly reduced the frequency of bowel movements. Furthermore, it was also associated with “significantly reduced levels of urinary 5-HIAA“, a marker for systemic serotonin levels, which are typically elevated in severe carcinoid syndrome and carcinoid heart disease. Essentially it works by reducing the manufacture of Serotonin so it may not have any effect on diarrhea not caused by syndrome (i.e. post-surgery etc).
For US patients only. Did you know the manufacturer had a Nurse Specialist Helpline?
Questions about XERMELO? Get the answers you need from a Carcinoid Syndrome diarrhea expert
Talk to a Clinical Nurse Educator (CNE) for the right support each step of the way. These CNEs have years of experience with Carcinoid Syndrome diarrhea and are dedicated to supporting you.
- Make XERMELO part of your routine and stay on track with treatment
- Easily identify Carcinoid Syndrome-friendly foods (you’ll receive a FREE Nutrition Guide, too)
- Learn about the role of hormones, including serotonin, in NETs
- Set up convenient text reminders to take your medication 3 times a day (optional)
Note: The CNEs can share general information about NETs and Carcinoid Syndrome but cannot provide medical advice on your specific condition.
Meet the CNEs here. They can help you.
March 2018 update
The March 2018 issue of Clinical Therapeutics provides the first report of the effects of XERMELO on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the TELESTAR study. You have to remember that XERMELO is approved for those with carcinoid syndrome diarrhea not adequately controlled by somatostatin analogues (author’s note – i.e not for diarrhea caused by (say) side effects of surgery).
Of the 120 patients with weight data available, up to 32.5% of patients treated with XERMELO experienced significant, dose-dependent weight gain (≥3% from baseline). Only 5.1% of patients on placebo experienced weight gain. Importantly, patients with weight gain experienced improvement in carcinoid syndrome control, as seen in reduction of bowel movement frequency and in parameters of nutritional status associated with positive changes in patient-reported outcomes compared with patients with stable weight or weight loss. Those patients also experienced reduced u5-HIAA levels. Patients with weight gain also experienced fewer serious adverse events than patients with stable weight or weight loss.
(see link below)
24th March 2021 update
A new Phase 3 clinical trial is being setup to “compare the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease”. As usual, the inclusion and exclusion criteria should be carefully examined. Read more – click here.
Resources for your perusal:
- You can read more about the trial data in a summary by Dr Matthew Kulke (Dana Farber) by CLICKING HERE (latest review from 2017 ASCO).
- There is also an excellent summary in video form by Dr Lowell Anthony (University of Kentucky) by CLICKING HERE. (“any reduction in diarrhea is meaningful“).
- The detailed output from the trial (results) can be found by CLICKING HERE.
- Great 2016 article from ASCO (American Society of Clinical Oncologists) can be found by CLICKING HERE.
- FDA Approval. CLICK HERE
- Lex Pharma press release on approval. CLICK HERE
- EU Approval (Ipsen Press Release). CLICK HERE
- The manufacturer Lex Pharma has established a dedicated site – CLICK HERE
- 2018 revised clinical data – CLICK HERE
Serotonin Video with myself and Dr Mike Morse
I made a video in 2019 with Dr Mike Morse sponsored by Lexicon Pharmaceuticals, Inc. It’s all about Carcinoid Syndrome with a slant towards hormones, in particular Serotonin Entitled “Likely Suspects: How Hormones May Lead to Carcinoid Syndrome – What People Living with Carcinoid Syndrome Need to Know”
You need to register to watch although some of you will already be registered and just need an email to login to see this webcast. Click on the link here: www.CarcinoidWebcast.com
Don’t forget to press the play button and ensure your sound is turned up, particularly on mobile devices.
Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.
Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)
Some of the key differences between Lanreotide and Octreotide long-acting are:1. Octreotide long-acting needs constituting prior to administration – Lanreotide comes prefilled. 2. Octreotide long-acting
(so called) Carcinoid Crisis is one thing that tends to raise concerns in patients and has been bubbling away in NET centres and in patient